Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Sandra Fernandes Lucas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Children's Hospital, Leeds, UK. Hauptthemen laut MEDLINE: Liver Transplantation, Immunosuppressive Agents, Sirolimus, Graft Rejection. Die Arbeit nennt 38 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Tacrolimus is the maintenance immunosuppression of choice in pediatric liver transplant (LT) recipients. However, in selective cases, sirolimus is used as an alternative immunosuppressive treatment. We aimed to review a single centre's experience of using sirolimus as an alternative to tacrolimus in pediatric LT recipients.
Methods
Single centre retrospective study of pediatric LT recipients who were started on sirolimus as an alternative immunosuppressant to tacrolimus. Children (< 16 years) who were started on sirolimus between May 2000 and May 2024 were included in the study.
Results
A total of 19 children were started on sirolimus following LT and followed up for a median of 4 years (range 0.4–12.8). Post‐transplant lymphoproliferative disorder (PTLD) was the most common reason for tacrolimus discontinuation and conversion to sirolimus ( n = 14), followed by tacrolimus‐related adverse effects ( n = 4) and disease recurrence ( n = 1). There were no cases of PTLD recurrence or biopsy‐confirmed rejection whilst on sirolimus. Proteinuria and hyperlipidaemia were the most common sirolimus side effects observed. Eighteen children remain on sirolimus to date, and none required discontinuation from side effects. In those with PTLD, 4 episodes of rejection occurred between the period of tacrolimus discontinuation and starting sirolimus (median immunosuppression‐free time of 5 months), with one child requiring regrafting due to chronic rejection.
Conclusion
The experience from our centre demonstrates sirolimus to be a safe and effective alternative to tacrolimus in a selected population of pediatric LT recipients. Further research with a larger sample size is required to confirm these findings and evaluate the long‐term safety of sirolimus in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leeds Children's Hospital, Leeds, UK.
ORCID-Profile: Sandra Fernandes Lucas, Penny North-Lewis
Zitieren
APA
Fernandes Lucas, S., Warner, S., North-Lewis, P., Mtegha, M. P., Jayaprakash, K., Karthikeyan, P., & Rajwal, S. (2025). Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children. Pediatric Transplantation. https://doi.org/10.1111/petr.70235
Vancouver
Fernandes Lucas S, Warner S, North-Lewis P, Mtegha MP, Jayaprakash K, Karthikeyan P, et al. Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children. Pediatric Transplantation. 2025. doi:10.1111/petr.70235
BibTeX
@article{FernandesLucas2025,
author = {Fernandes Lucas, Sandra and Warner, Suzan and North-Lewis, Penny and Mtegha, Marumbo Paul and Jayaprakash, Kavitha and Karthikeyan, Palaniswamy and Rajwal, Sanjay},
title = {Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70235}
}
EUVIMED